Psychedelics are serotonin 2A receptor agonists that can lead to profound changes in
perception, cognition and mood. In this review, we focus on the basic neurobiology …

Psychedelic drugs including psilocybin, N, N ʹ-dimethyltryptamine (DMT) and lysergic acid
diethylamide (LSD) are undergoing a renaissance as potentially useful drugs for various …

Decreased dendritic spine density in the cortex is a hallmark of several neuropsychiatric
diseases, and the ability to promote cortical neuron growth has been hypothesized to …

There is considerable interest in screening ultralarge chemical libraries for ligand discovery,
both empirically and computationally,,–. Efforts have focused on readily synthesizable …

Drugs that target the human serotonin 2A receptor (5-HT2AR) are used to treat
neuropsychiatric diseases; however, many have hallucinogenic effects, hampering their use …

Psilocybin is a serotonergic psychedelic with untapped therapeutic potential. There are hints
that the use of psychedelics can produce neural adaptations, although the extent and …

Psychedelics are a broad class of drugs defined by their ability to induce an altered state of
consciousness,. These drugs have been used for millennia in both spiritual and medicinal …

This paper provides a critical review of several possible mechanisms at different levels of
analysis underlying the effects and therapeutic potential of psychedelics. At the (1) …

The MRGPRX family of receptors (MRGPRX1–4) is a family of mas-related G-protein-
coupled receptors that have evolved relatively recently. Of these, MRGPRX2 and MRGPRX4 …

The emerging therapeutic efficacy of ketamine and classical psychedelics for depression
has inspired tremendous interest in the underlying neurobiological mechanisms. We review …